EGTXS Stock Overview
A pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Egetis Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 6.95 |
| 52 Week High | SEK 0 |
| 52 Week Low | SEK 0 |
| Beta | 1.43 |
| 1 Month Change | 0% |
| 3 Month Change | 28.14% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -19.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| EGTXS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 9.4% | 3.3% |
| 1Y | n/a | -18.1% | 10.6% |
Return vs Industry: Insufficient data to determine how EGTXS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how EGTXS performed against the UK Market.
Price Volatility
| EGTXS volatility | |
|---|---|
| EGTXS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: EGTXS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine EGTXS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 34 | Nicklas Westerholm | www.egetis.com |
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020.
Egetis Therapeutics AB (publ) Fundamentals Summary
| EGTXS fundamental statistics | |
|---|---|
| Market cap | SEK 1.34b |
| Earnings (TTM) | -SEK 319.40m |
| Revenue (TTM) | SEK 70.80m |
19.0x
P/S Ratio-4.2x
P/E RatioIs EGTXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EGTXS income statement (TTM) | |
|---|---|
| Revenue | SEK 70.80m |
| Cost of Revenue | SEK 206.50m |
| Gross Profit | -SEK 135.70m |
| Other Expenses | SEK 183.70m |
| Earnings | -SEK 319.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 08, 2024
| Earnings per share (EPS) | -1.09 |
| Gross Margin | -191.67% |
| Net Profit Margin | -451.13% |
| Debt/Equity Ratio | 27.1% |
How did EGTXS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/15 19:16 |
| End of Day Share Price | 2024/07/18 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Egetis Therapeutics AB (publ) is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Patrick Langstrom | ABG Sundal Collier Sponsored |
| Oscar Haffen Lamm | Bryan Garnier & Co |